Skip to main content

Tracking our ESG performance

We track our performance based on our ability to discover and deliver innovative medicines, unlock the full potential of diverse and talented teams and partners and innovate with integrity and intention to advance long-term patient health and business resiliency.

 

We discover and deliver innovative medicines that solve serious health issues and enhance people’s lives by unlocking the full potential of diverse and talented teams – and partners – to deliver today and into the future. We innovate with integrity and intention to advance long-term patient health and business resiliency. This is our commitment to better our society.
 

ESG Action Report

Product innovation

We strive to make a remarkable impact on patients and drive sustainable growth by consistently discovering and delivering innovative medicines that address serious health issues and enhance people’s lives. In 2020, we achieved 12 new product or indication approvals or expansions. These included new treatments for rheumatoid arthritis, moderate to severe plaque psoriasis and previously untreated chronic lymphocytic leukemia. 

Patient access and patient affordability

We believe everyone who needs our medicines should be able to get them. Our patient assistance programs serve as an important safety net for patients who lack insurance or whose health plans limit coverage for our treatments. In 2020, nearly 155,000 patients received AbbVie medicine at no cost through our patient assistance programs. 

Human capital management

We believe purposeful work drives meaningful change. We nurture diverse talent to solve the most complex challenges and create remarkable impact in people’s lives. That why we’ve made a Commitment to Equity, Equality, Diversity & Inclusion based on our corporate principle of Embracing Diversity & Inclusion and why we have also signed three commitments – the CEO Action for Diversity & Inclusion™ pledge, Paradigm for Parity® and Business Coalition for the Equality Act. In 2020, 49% of management positions (manager-level and above) were held by women.

Patient health and engagement

We continuously strive to improve health outcomes for patients around the world. We offer a wide range of disease and country-specific patient programs that provide meaningful, informative and empowering support to patients who have been prescribed AbbVie medicines. We also seek to understand the people’s perspective on living with their condition so that we can better support patients and customers now and into the future. Additionally, we support independent educational grants and continuing medical education to ensure both physicians and patients have access to meaningful independent educational resources around new and emerging sciences and standards of care that contribute to improved health outcomes. In 2020, we reached more than 1.1 million patients and more than 177,000 health care providers through independent educations grants. 

Product quality and safety

We are committed to delivering safe and effective, quality products and medicines through robust quality systems. Once our medicines are approved and marketed, we maintain a robust pharmacovigilance program to ensure continued safety. We regularly monitor for safety signals, and we routinely achieve over 98% on-time expedited reporting of adverse events to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). 

The AbbVie ESG Action Report includes our full reporting on all relevant ESG metrics.

For the Well-Being of Our Patients

For the Resilience
of Our Business